Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
The interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) induces exhaustions of cytotoxic lymphocytes in the tumor microenvironment, which facilitates tumor immune evasion. PD-1/PD-L1 blockade therapy, which prevents the receptors and ligands fr...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.00726/full |
id |
doaj-7a113ee3f4f34205b069d9f02b8ceaea |
---|---|
record_format |
Article |
spelling |
doaj-7a113ee3f4f34205b069d9f02b8ceaea2020-11-24T21:46:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-07-011010.3389/fphar.2019.00726466024Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian PopulationsJiqiao Yang0Jiqiao Yang1Jiqiao Yang2Xiujing He3Xiujing He4Qing Lv5Qing Lv6Jing Jing7Hubing Shi8Hubing Shi9Laboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaClinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Breast Surgery, West China Hospital, Sichuan University, Chengdu, ChinaLaboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaClinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaClinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Breast Surgery, West China Hospital, Sichuan University, Chengdu, ChinaClinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaLaboratory of Tumor Targeted and Immune Therapy, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaClinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaThe interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) induces exhaustions of cytotoxic lymphocytes in the tumor microenvironment, which facilitates tumor immune evasion. PD-1/PD-L1 blockade therapy, which prevents the receptors and ligands from binding to each other, disrupts the T-cell exhaustion signaling, thereby increasing antitumor immunity. Inspiringly, it has revolutionized the treatment of many different types of cancers including non-small-cell lung carcinoma, melanoma, lymphoma, and so on. However, with the intention of generating an antitumor immune response, PD-1/PD-L1 blockade may also lead to a spectrum of side effects. The profile of adverse events (AEs) of PD-1/PD-L1 blockade is not exactly the same with other immune checkpoint blockades, such as blockade of cytotoxic T-lymphocyte-associated protein 4. Although cutaneous, gastrointestinal, and pulmonary systems are common victims, AEs of PD-1/PD-L1 blockade might occur in any other organ system of the human body. These toxicities can be life-threatening if not managed promptly, and proper treatment intervention is imperative for optimal control and prevention of severe damage. Currently, clinical practice for the management of AEs in PD-1/PD-L1 blockade remains sporadic and variable. The majority of initial clinical trials were carried out in Caucasians. The trials of multiple races usually included a small portion of Asian participants, and results were calculated and interpreted for the entire included subjects without any race-specific conclusions. Therefore, the information on PD-1/PD-L1 blockade in Asians is far from systematic or comprehensive. Recently, as the results of clinical trials of anti-PD-1/PD-L1 agents in Asian populations have been gradually released, we summarized current evidence with a specific focus on the Asian population, hoping to outline strategies and offer guidance on the management of AEs in cancer patients treated with PD-1/PD-L1 blockade in the Asian world.https://www.frontiersin.org/article/10.3389/fphar.2019.00726/fullprogrammed cell death protein 1programmed death-ligand 1adverse eventAsiancancerimmunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jiqiao Yang Jiqiao Yang Jiqiao Yang Xiujing He Xiujing He Qing Lv Qing Lv Jing Jing Hubing Shi Hubing Shi |
spellingShingle |
Jiqiao Yang Jiqiao Yang Jiqiao Yang Xiujing He Xiujing He Qing Lv Qing Lv Jing Jing Hubing Shi Hubing Shi Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations Frontiers in Pharmacology programmed cell death protein 1 programmed death-ligand 1 adverse event Asian cancer immunotherapy |
author_facet |
Jiqiao Yang Jiqiao Yang Jiqiao Yang Xiujing He Xiujing He Qing Lv Qing Lv Jing Jing Hubing Shi Hubing Shi |
author_sort |
Jiqiao Yang |
title |
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations |
title_short |
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations |
title_full |
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations |
title_fullStr |
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations |
title_full_unstemmed |
Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations |
title_sort |
management of adverse events in cancer patients treated with pd-1/pd-l1 blockade: focus on asian populations |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2019-07-01 |
description |
The interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) induces exhaustions of cytotoxic lymphocytes in the tumor microenvironment, which facilitates tumor immune evasion. PD-1/PD-L1 blockade therapy, which prevents the receptors and ligands from binding to each other, disrupts the T-cell exhaustion signaling, thereby increasing antitumor immunity. Inspiringly, it has revolutionized the treatment of many different types of cancers including non-small-cell lung carcinoma, melanoma, lymphoma, and so on. However, with the intention of generating an antitumor immune response, PD-1/PD-L1 blockade may also lead to a spectrum of side effects. The profile of adverse events (AEs) of PD-1/PD-L1 blockade is not exactly the same with other immune checkpoint blockades, such as blockade of cytotoxic T-lymphocyte-associated protein 4. Although cutaneous, gastrointestinal, and pulmonary systems are common victims, AEs of PD-1/PD-L1 blockade might occur in any other organ system of the human body. These toxicities can be life-threatening if not managed promptly, and proper treatment intervention is imperative for optimal control and prevention of severe damage. Currently, clinical practice for the management of AEs in PD-1/PD-L1 blockade remains sporadic and variable. The majority of initial clinical trials were carried out in Caucasians. The trials of multiple races usually included a small portion of Asian participants, and results were calculated and interpreted for the entire included subjects without any race-specific conclusions. Therefore, the information on PD-1/PD-L1 blockade in Asians is far from systematic or comprehensive. Recently, as the results of clinical trials of anti-PD-1/PD-L1 agents in Asian populations have been gradually released, we summarized current evidence with a specific focus on the Asian population, hoping to outline strategies and offer guidance on the management of AEs in cancer patients treated with PD-1/PD-L1 blockade in the Asian world. |
topic |
programmed cell death protein 1 programmed death-ligand 1 adverse event Asian cancer immunotherapy |
url |
https://www.frontiersin.org/article/10.3389/fphar.2019.00726/full |
work_keys_str_mv |
AT jiqiaoyang managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT jiqiaoyang managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT jiqiaoyang managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT xiujinghe managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT xiujinghe managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT qinglv managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT qinglv managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT jingjing managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT hubingshi managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations AT hubingshi managementofadverseeventsincancerpatientstreatedwithpd1pdl1blockadefocusonasianpopulations |
_version_ |
1725899963553021952 |